MedTrace Logo

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

NCT06012708 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-01-08

No results posted yet for this study

Summary

To evaluate the safety and tolerability of the combination therapy of KN510 and KN713 and determine the MTD and RP2D in patients with advanced solid tumors.

Conditions

Interventions

DRUG

KN510 60mg/day + KN713 60mg/day

Once daily with 28 days (4 weeks) as one cycle.

DRUG

KN510 120mg/day + KN713 60mg/day

Once daily with 28 days (4 weeks) as one cycle.

DRUG

KN510 120mg/day + KN713 90mg/day

Once daily with 28 days (4 weeks) as one cycle.

DRUG

KN510 120mg/day + KN713 120mg/day

Once daily with 28 days (4 weeks) as one cycle.

Sponsors & Collaborators

  • New Cancer Cure-Bio Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-11
Primary Completion
2024-11-05
Completion
2024-12-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06012708 on ClinicalTrials.gov